Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Processed Meat and Risk of Renal Cell and Bladder Cancers.

Rosato V, Negri E, Serraino D, Montella M, Libra M, Lagiou P, Facchini G, Ferraroni M, Decarli A, La Vecchia C.

Nutr Cancer. 2018 Apr;70(3):418-424. doi: 10.1080/01635581.2018.1445764. Epub 2018 Mar 23.

PMID:
29570985
2.

Change in FGF-2 circulating levels after arterial embolization in patients with bone metastases.

Rossi G, Salerno M, Granchi D, Cenni E, Facchini G, Baldini N.

Neoplasma. 2018;65(2):262-268. doi: 10.4149/neo_2018_170204N74.

PMID:
29534588
3.

Diffuse lung disease associated with neurofibromatosis type-1 can also affect children.

Spinnato P, Facchini G, Bazzocchi A, Albisinni U.

World J Pediatr. 2018 Mar 7. doi: 10.1007/s12519-018-0149-3. [Epub ahead of print] No abstract available.

PMID:
29516392
4.

Successful selective arterial embolizations for bone metastases in renal cell carcinoma integrated with systemic therapies: A case report.

Gatto L, Facchini G, Saponara M, Nannini M, Rossi G, Di Scioscio V, Biasco G, Pantaleo MA.

Radiol Case Rep. 2017 Aug 16;12(4):775-779. doi: 10.1016/j.radcr.2017.07.008. eCollection 2017 Dec.

5.

Biopsy is not necessary for the diagnosis of soft tissue hemangiomas.

Rimondi E, Mavrogenis AF, Errani C, Calabrò T, Bazzocchi A, Facchini G, Donatiello S, Spinnato P, Vanel D, Albisinni U, Pelotti P.

Radiol Med. 2018 Feb 23. doi: 10.1007/s11547-018-0862-y. [Epub ahead of print]

PMID:
29476440
6.

Health-related quality of life and psychosocial implications in testicular cancer survivors. A literature review.

Cappuccio F, Rossetti S, Cavaliere C, Iovane G, Taibi R, D'Aniello C, Imbimbo C, Facchini S, Abate V, Barberio D, Facchini G.

Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):645-661. doi: 10.26355/eurrev_201802_14290.

PMID:
29461592
7.

Exploring the molecular aspects associated with testicular germ cell tumors: a review.

Facchini G, Rossetti S, Cavaliere C, D'Aniello C, Di Franco R, Iovane G, Grimaldi G, Piscitelli R, Muto P, Botti G, Perdonà S, Veneziani BM, Berretta M, Montanari M.

Oncotarget. 2017 Nov 3;9(1):1365-1379. doi: 10.18632/oncotarget.22373. eCollection 2018 Jan 2. Review.

8.

Proanthocyanidins and the risk of prostate cancer in Italy.

Praud D, Parpinel M, Guercio V, Bosetti C, Serraino D, Facchini G, Montella M, La Vecchia C, Rossi M.

Cancer Causes Control. 2018 Feb;29(2):261-268. doi: 10.1007/s10552-018-1002-7. Epub 2018 Jan 19.

PMID:
29350310
9.

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.

Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.

PMID:
29326030
10.

Ipilimumab for the treatment of metastatic prostate cancer.

Alaia C, Boccellino M, Zappavigna S, Amler E, Quagliuolo L, Rossetti S, Facchini G, Caraglia M.

Expert Opin Biol Ther. 2018 Feb;18(2):205-213. doi: 10.1080/14712598.2018.1420777. Epub 2017 Dec 28.

PMID:
29271259
11.

Testicular cancer from diagnosis to epigenetic factors.

Boccellino M, Vanacore D, Zappavigna S, Cavaliere C, Rossetti S, D'Aniello C, Chieffi P, Amler E, Buonerba C, Di Lorenzo G, Di Franco R, Izzo A, Piscitelli R, Iovane G, Muto P, Botti G, Perdonà S, Caraglia M, Facchini G.

Oncotarget. 2017 Sep 18;8(61):104654-104663. doi: 10.18632/oncotarget.20992. eCollection 2017 Nov 28. Review.

12.

Epigenetic Changes Induced by Green Tea Catechins a re Associated with Prostate Cancer.

Giudice A, Montella M, Boccellino M, Crispo A, D'Arena G, Bimonte S, Facchini G, Ciliberto G, Botti G, Quagliuolo L, Caraglia M, Capunzo M.

Curr Mol Med. 2017;17(6):405-420. doi: 10.2174/1566524018666171219101937.

PMID:
29256350
13.

The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies.

Sassi C, Stanzani M, Lewis RE, Facchini G, Bazzocchi A, Cavo M, Battista G.

Br J Radiol. 2018 Feb;91(1083):20170220. doi: 10.1259/bjr.20170220. Epub 2018 Jan 10.

PMID:
29212355
14.

Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment.

Di Franco R, Borzillo V, Ravo V, Falivene S, Romano FJ, Muto M, Cammarota F, Totaro G, Ametrano G, Rossetti S, Cavaliere C, D' Aniello C, Iovane G, Porricelli MA, Berretta M, Botti G, Starace L, Salvia E, Facchini G, Muto P.

Neuroradiol J. 2018 Feb;31(1):18-26. doi: 10.1177/1971400917744885. Epub 2017 Dec 5.

PMID:
29206077
15.

Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results.

Di Francia R, Atripaldi L, Di Martino S, Fierro C, Muto T, Crispo A, Rossetti S, Facchini G, Berretta M.

Front Pharmacol. 2017 Nov 7;8:797. doi: 10.3389/fphar.2017.00797. eCollection 2017.

16.

Toxic effects of phytol and retinol on human glioblastoma cells are associated with modulation of cholesterol and fatty acid biosynthetic pathways.

Facchini G, Ignarro RS, Rodrigues-Silva E, Vieira AS, Lopes-Cendes I, Castilho RF, Rogerio F.

J Neurooncol. 2018 Feb;136(3):435-443. doi: 10.1007/s11060-017-2672-9. Epub 2017 Nov 20.

PMID:
29159775
17.

Coffee Decreases the Risk of Endometrial Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies.

Lafranconi A, Micek A, Galvano F, Rossetti S, Del Pup L, Berretta M, Facchini G.

Nutrients. 2017 Nov 9;9(11). pii: E1223. doi: 10.3390/nu9111223. Review.

18.

Associations of dietary carbohydrates, glycaemic index and glycaemic load with risk of bladder cancer: a case-control study.

Augustin LSA, Taborelli M, Montella M, Libra M, La Vecchia C, Tavani A, Crispo A, Grimaldi M, Facchini G, Jenkins DJA, Botti G, Serraino D, Polesel J.

Br J Nutr. 2017 Nov;118(9):722-729. doi: 10.1017/S0007114517002574. Epub 2017 Oct 9.

PMID:
28990544
19.

Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G.

Oncotarget. 2017 Sep 22;8(37):62816. doi: 10.18632/oncotarget.20631. eCollection 2017 Sep 22.

20.

Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis.

Di Franco R, Borzillo V, Ravo V, Ametrano G, Cammarota F, Rossetti S, Romano FJ, D'Aniello C, Cavaliere C, Iovane G, Porricelli MA, Muto M, Berretta M, Facchini G, Muto P.

Eur Rev Med Pharmacol Sci. 2017 Aug;21(16):3563-3575.

21.

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.

Rossetti S, D'Aniello C, Iovane G, Scagliarini S, Laterza MM, De Vita F, Savastano C, Cartenì G, Porricelli MA, Berretta M, Pisconti S, Facchini G, Cavaliere C.

Front Pharmacol. 2017 Jul 20;8:484. doi: 10.3389/fphar.2017.00484. eCollection 2017.

22.

Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.

Di Lorenzo G, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Federico P, Daniele B, Morelli F, Bellelli T, Ferro M, De Placido S, Buonerba C.

Eur Urol Focus. 2017 Apr 8. pii: S2405-4569(17)30083-4. doi: 10.1016/j.euf.2017.03.015. [Epub ahead of print]

PMID:
28753882
23.

A rare case of malignant solitary fibrous tumor in prostate with review of the literature.

Ronchi A, La Mantia E, Gigantino V, Perdonà S, De Sio M, Facchini G, Franco R, De Chiara A.

Diagn Pathol. 2017 Jul 7;12(1):50. doi: 10.1186/s13000-017-0640-5. Review.

24.

ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.

Botti G, Malzone MG, La Mantia E, Montanari M, Vanacore D, Rossetti S, Quagliariello V, Cavaliere C, Di Franco R, Castaldo L, Ametrano G, Cappuccio F, Romano FJ, Piscitelli R, Pepe MF, D'Aniello C, Facchini G.

Int J Med Sci. 2017 Apr 21;14(6):554-559. doi: 10.7150/ijms.17890. eCollection 2017. Review.

25.

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.

Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Daniele B, Morelli F, Ferro M, Puglia L, Izzo M, Montanaro V, Bellelli T, Vitrone F, De Placido S, Buonerba C, Di Lorenzo G.

Medicine (Baltimore). 2017 Jun;96(24):e6817. doi: 10.1097/MD.0000000000006817.

26.

Ultraviolet A photosensitivity profile of dexchlorpheniramine maleate and promethazine-based creams: Anti-inflammatory, antihistaminic, and skin barrier protection properties.

Facchini G, Eberlin S, Clerici SP, Alves Pinheiro ALT, Costa A.

J Cosmet Dermatol. 2017 Dec;16(4):e59-e67. doi: 10.1111/jocd.12349. Epub 2017 Jun 7.

PMID:
28593645
27.

Spinal osteoid osteoma: efficacy and safety of radiofrequency ablation.

Albisinni U, Facchini G, Spinnato P, Gasbarrini A, Bazzocchi A.

Skeletal Radiol. 2017 Aug;46(8):1087-1094. doi: 10.1007/s00256-017-2662-1. Epub 2017 May 11.

PMID:
28497160
28.

Micrornas in prostate cancer: an overview.

Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D'Aniello C, Di Franco R, Romano FJ, Montanari M, La Mantia E, Piscitelli R, Nocerino F, Cappuccio F, Grimaldi G, Izzo A, Castaldo L, Pepe MF, Malzone MG, Iovane G, Ametrano G, Stiuso P, Quagliuolo L, Barberio D, Perdonà S, Muto P, Montella M, Maiolino P, Veneziani BM, Botti G, Caraglia M, Facchini G.

Oncotarget. 2017 Jul 25;8(30):50240-50251. doi: 10.18632/oncotarget.16933. Review.

29.

Epithelial-mesenchymal transition in prostate cancer: an overview.

Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E, Iovane G, Piscitelli R, Muscariello R, Berretta M, Perdonà S, Muto P, Botti G, Bianchi AAM, Veneziani BM, Facchini G.

Oncotarget. 2017 May 23;8(21):35376-35389. doi: 10.18632/oncotarget.15686. Review.

30.

Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.

Conteduca V, Caffo O, Lolli C, Aieta M, Scarpi E, Bianchi E, Maines F, Schepisi G, Salvi S, Massari F, Carrozza F, Veccia A, Chiuri VE, Campadelli E, Facchini G, De Giorgi U.

Prostate. 2017 Jun;77(9):1012-1019. doi: 10.1002/pros.23357. Epub 2017 Apr 20.

PMID:
28429372
31.

Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G.

Oncotarget. 2017 May 2;8(18):30606-30616. doi: 10.18632/oncotarget.16725. Review. Erratum in: Oncotarget. 2017 Sep 22;8(37):62816.

32.

Family history of cancer and the risk of bladder cancer: A case-control study from Italy.

Turati F, Bosetti C, Polesel J, Serraino D, Montella M, Libra M, Facchini G, Ferraroni M, Tavani A, La Vecchia C, Negri E.

Cancer Epidemiol. 2017 Jun;48:29-35. doi: 10.1016/j.canep.2017.03.003. Epub 2017 Mar 28.

PMID:
28363161
33.

Serum and tissue markers in colorectal cancer: State of art.

Berretta M, Alessandrini L, De Divitiis C, Nasti G, Lleshi A, Di Francia R, Facchini G, Cavaliere C, Buonerba C, Canzonieri V.

Crit Rev Oncol Hematol. 2017 Mar;111:103-116. doi: 10.1016/j.critrevonc.2017.01.007. Epub 2017 Jan 27. Review.

PMID:
28259285
34.

Honokiol protects skin cells against inflammation, collagenolysis, apoptosis, and senescence caused by cigarette smoke damage.

Costa A, Facchini G, Pinheiro ALTA, da Silva MS, Bonner MY, Arbiser J, Eberlin S.

Int J Dermatol. 2017 Jul;56(7):754-761. doi: 10.1111/ijd.13569. Epub 2017 Feb 22.

PMID:
28229451
35.

Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey.

Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A, Nasti G, Fisichella R, Romano C, De Divitiis C, Taibi R, Fiorica F, Di Francia R, Di Mari A, Del Pup L, Crispo A, De Paoli P, Santorelli A, Quagliariello V, Iaffaioli RV, Tirelli U, Facchini G.

Oncotarget. 2017 Apr 11;8(15):24401-24414. doi: 10.18632/oncotarget.14224.

36.

A comprehensive review of pulsed radiofrequency in the treatment of pain associated with different spinal conditions.

Facchini G, Spinnato P, Guglielmi G, Albisinni U, Bazzocchi A.

Br J Radiol. 2017 May;90(1073):20150406. doi: 10.1259/bjr.20150406. Epub 2017 Feb 10. Review.

PMID:
28186832
37.

Current and Emerging Treatments for Metastatic Renal Cell Carcinoma.

Cavaliere C, D Aniello C, Pepa CD, Pisconti S, Berretta M, Facchini G.

Curr Cancer Drug Targets. 2017 Feb 8. doi: 10.2174/1568009617666170209094030. [Epub ahead of print]

PMID:
28183256
38.

MELANOMA ADJUVANT TREATMENT: current insight and clinical features.

D Aniello C, Perri F, Scarpati GD, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C.

Curr Cancer Drug Targets. 2017 Feb 8. doi: 10.2174/1568009617666170208163714. [Epub ahead of print]

PMID:
28183255
39.

Optimal Management of Prostate Cancer Based on its Natural Clinical History.

Facchini G, Perri F, Misso G, D Aniello C, Scarpati GD, Rossetti S, Pepa CD, Pisconti S, Unteregger G, Cossu A, Caraglia M, Berretta M, Cavaliere C.

Curr Cancer Drug Targets. 2017 Feb 8. doi: 10.2174/1568009617666170209093101. [Epub ahead of print]

PMID:
28183253
40.

The Role of Target Therapy in the Treatment of Gastrointestinal Non Colorectal Cancers: Clinical Impact and Cost Consideration.

Berretta M, Di Francia R, De Diviitis C, Nasti G, Canzonieri V, Caraglia M, Facchini G, Tirelli U.

Curr Cancer Drug Targets. 2017 Feb 8. doi: 10.2174/1568009617666170208162058. [Epub ahead of print]

PMID:
28183250
41.

Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.

Di Franco R, Borzillo V, Ravo V, Ametrano G, Falivene S, Cammarota F, Rossetti S, Romano FJ, D'Aniello C, Cavaliere C, Iovane G, Piscitelli R, Berretta M, Muto P, Facchini G.

Oncotarget. 2017 Mar 7;8(10):17383-17395. doi: 10.18632/oncotarget.14798. Review.

42.

First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.

Buti S, Bersanelli M, Maines F, Facchini G, Gelsomino F, Zustovich F, Santoni M, Verri E, De Giorgi U, Masini C, Morelli F, Vitale MG, Sava T, Prati G, Librici C, Fraccon AP, Fornarini G, Maruzzo M, Leonardi F, Caffo O.

Clin Genitourin Cancer. 2017 Aug;15(4):e609-e614. doi: 10.1016/j.clgc.2016.12.024. Epub 2016 Dec 29.

PMID:
28108284
43.

Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.

Bergamini A, Pisano C, Di Napoli M, Arenare L, Della Pepa C, Tambaro R, Facchini G, Gargiulo P, Rossetti S, Mangili G, Pignata S, Cecere SC.

Gynecol Oncol. 2017 Jan;144(1):72-76. doi: 10.1016/j.ygyno.2016.10.023. Epub 2016 Oct 27.

PMID:
28094039
44.

Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.

Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, Perin T, Canzonieri V.

Oncotarget. 2017 Feb 21;8(8):14192-14220. doi: 10.18632/oncotarget.13929. Review.

45.

Antioxidant diet and genotyping as tools for the prevention of liver disease.

Di Francia R, Rinaldi L, Cillo M, Varriale E, Facchini G, D'Aniello C, Marotta G, Berretta M.

Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5155-5163. Review.

46.

Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells.

Ignarro RS, Facchini G, de Melo DR, Pelizzaro-Rocha KJ, Ferreira CV, Castilho RF, Rogerio F.

Neurosci Lett. 2017 Jan 18;638:189-195. doi: 10.1016/j.neulet.2016.12.035. Epub 2016 Dec 19.

PMID:
28007652
47.

How effective is embolization with N-2-butyl-cyanoacrylate for aneurysmal bone cysts?

Rossi G, Mavrogenis AF, Facchini G, Bartalena T, Rimondi E, Renzulli M, Andreone A, Durante S, Angelini A, Errani C.

Int Orthop. 2017 Aug;41(8):1685-1692. doi: 10.1007/s00264-016-3364-3. Epub 2016 Dec 8.

PMID:
27933423
48.

Tumour biomarkers: homeostasis as a novel prognostic indicator.

Falco M, Palma G, Rea D, De Biase D, Scala S, D'Aiuto M, Facchini G, Perdonà S, Barbieri A, Arra C.

Open Biol. 2016 Dec;6(12). pii: 160254. Review.

49.

Corrigendum: Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale".

Cecere SC, Rossetti S, Cavaliere C, Della Pepa C, Di Napoli M, Crispo A, Iovane G, Piscitelli R, Sorrentino D, Ciliberto G, Maiolino P, Muto P, Perdonà S, Berretta M, Pignata S, Facchini G, D'Aniello C.

Front Pharmacol. 2016 Dec 5;7:468. eCollection 2016.

50.

Letter to the Editor - Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment.

D'Aniello C, Cavaliere C, Fiorica F, Facchini G.

Eur Rev Med Pharmacol Sci. 2016 Nov;20(22):4626-4627. No abstract available.

Supplemental Content

Loading ...
Support Center